Last edition
News about " ANZ Licensing Pact Between Formosa and Arrotex"
Advanced Drug Formulation Platform Drives ANZ Licensing Pact Between Formosa and Arrotex
Taiwan-based clinical-stage biotech company Formosa Pharmaceuticals has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. for the commercialization of clobetasol propionate ophthalmic suspension 0.05% (APP13007) in Australia and New Zealand.
ANZ Licensing Pact Between Formosa And Arrotex | 24/02/2026 | By Darshana | 106
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members